Axicabtagene Ciloleucel (Yescarta) Launches China's First Outcomes-Based Payment Plan for Lymphoma, Offering Up to RMB 600,000 Refund
Fosun Kairos
Developer of Tumor Immune Cell Therapy Technologies and Products
Medi Cover
Innovative Commercial Insurance Solution Provider
According to an announcement on the official WeChat account of Fosun Kite, recently, in collaboration with Medi Cover, a health management and patient comprehensive service platform under Sinopharm Holding, they jointly launched China’s first performance-based payment plan for lymphoma using Yikaida. The CAR-T therapy Axicabtagene Ciloleucel Injection (brand name: Yikaida), originally priced at 1.2 million yuan per dose, will offer eligible patients up to 600,000 yuan if complete remission (CR) is not achieved after use. This initiative marks China’s first innovative payment model based on therapeutic outcomes for lymphoma medication, making Yikaida the first biologic drug in China to adopt a performance-based payment model.
According to the report by People's Daily Health Client, "If complete remission is not achieved within 3 months, even if there is some efficacy but it does not reach complete remission, under this plan, half of the out-of-pocket payment for the drug will still be refunded. If the patient fully self-finances the medication, they can receive a maximum refund of 600,000 RMB for the drug cost. However, if the patient has already participated in insurance programs like Shanghai HuHui Insurance and after insurance reimbursement, their out-of-pocket drug expenses are 700,000 RMB, they will receive a refund of half, i.e., 350,000 RMB, significantly reducing the overall treatment costs." According to a relevant representative from Fosun Kite Biotechnology Co., Ltd., Yikaida China’s first lymphoma value-based payment plan will strictly follow the assessment of complete response (CR) results based on the latest international authoritative standard, the '2014 Lugano Evaluation Criteria' (targeting lymphoma efficacy evaluation).
Yikaida is the Yescarta product introduced by Fosun Kite from Gilead's subsidiary Kite. Since its approval for marketing in China in June 2021, Yikaida has been approved for two indications in China: for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after receiving second-line or later systemic therapy, and for adult patients with large B-cell lymphoma who are ineffective with first-line immunochemotherapy or relapse within 12 months after first-line immunochemotherapy. In addition, Yikaida's third indication, for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma (r/r iNHL), including adult patients with follicular lymphoma and marginal zone lymphoma, has been approved for clinical trials and included in the breakthrough therapy drug program.
As of now, Fosun Kite has not disclosed the specific sales performance of Yikaida, but as of 2023, Yikaida has successfully treated over 600 patients with relapsed/refractory large B-cell lymphoma.
Recommended Reading
Fully Open for Business, Welcome to Visit >>
For advertising, conference cooperation, corporate communication, etc., please contact 400-689-7892.